Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

Inovio Pharmaceuticals NASDAQ: INO shareholders approved all proposals presented at the company's 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending Dec. 31, 2026.